Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natalizumab effects on BBB and myelin in MS
NCT05177718Phase 4Terminated
- Sponsor
- Vanderbilt University Medical Center
- Start
- Sep 2022
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of natalizumab in multiple sclerosis (MS), sponsored by Vanderbilt University Medical Center. Primary endpoint: Volume Transfer Constant at 12 months. Started Sep 2022; status: terminated.
02
Drugs
natalizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05177718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05177718.